¿Es necesaria la vacunación contra el meningococo B en el mundo pos-COVID-19?

Amanda Izeli Portilho, Elizabeth De Gaspari, .

DOI: https://doi.org/10.7705/biomedica.7423
Palabras clave: Neisseria meningitidis, infecciones meningocócicas, infecciones del sistema respiratorio, infecciones por coronavirus
Resumen Autores/as Descargas Referencias bibliográficas Cómo citar

Resumen

Neisseria meningitidis es la principal causa de meningitis bacteriana en el mundo y es transmitida mediante secreciones respiratorias. La meningitis es un grave problema de salud pública debido a sus grandes tasas de morbilidad y mortalidad, y por el riesgo de generar epidemias.
Aunque existen vacunas para prevenir la enfermedad meningocócica, la infección por el serogrupo B sigue siendo un desafío, ya que muchos países no han incluido estas vacunas en sus programas nacionales de inmunización. Además, datos recientes sugieren la persistencia de infecciones causadas por el serogrupo B de N. meningitidis durante la pandemia de COVID-19 y un incremento en los niveles de enfermedad meningocócica tras su contención. Esta información coincide con observaciones previas que afirman que los virus respiratorios facilitan las infecciones bacterianas respiratorias.
Este ensayo pretende presentar datos epidemiológicos de la enfermedad meningocócica y discutir aquellos estudios que resaltan la complejidad de la prevención de las infecciones bacterianas y virales.

Descargas

Los datos de descargas todavía no están disponibles.
  • Amanda Izeli Portilho Centro de Imunologia do Instituto Adolfo Lutz, São Paulo, SP, Brasil; Programa de Pós-Graduação Interunidades em Biotecnologia, Universidade de São Paulo, São Paulo, SP, Brasil https://orcid.org/0000-0003-0875-5910
  • Elizabeth De Gaspari Centro de Imunologia do Instituto Adolfo Lutz, São Paulo, SP, Brasil; Programa de Pós-Graduação Interunidades em Biotecnologia, Universidade de São Paulo, São Paulo, SP, Brasil https://orcid.org/0000-0001-8332-2248

Referencias bibliográficas

1. Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against meningococcal diseases. Microorganisms. 2020;8:1521. https://doi.org/10.3390/microorganisms8101521

2. Pardo De Santayana C, Tin Tin Htar M, Findlow J, Balmer P. Epidemiology of invasive meningococcal disease worldwide from 2010-2019: A literature review. Epidemiol Infect. 2023;151:1-9. https://doi.org/10.1017/S0950268823000328

3. Spinosa MR, Progida C, Tala A, Cogli L, Alifano P, Bucci C. The Neisseria meningitidis capsule is important for intracellular survival in human cells. Infect Immun. 2007;75:3594-603. https://doi.org/10.1128/IAI.01945-06

4. Pizza M, Rappuoli R. Neisseria meningitidis: Pathogenesis and immunity. Curr Opin Microbiol. 2015;23:68-72. https://doi.org/10.1016/j.mib.2014.11.006

5. Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis: Implications for vaccine development and pathogenesis. Lancet. 1983;322:355-7. https://doi.org/10.1016/s0140-6736(83)90340-9

6. Finne J, Finne U, Deagostini-Bazin H, Goridis C. Ocurrence of α2–8 linked polysialosyl units in a neural cell adhesion molecule. Biochem Biophys Res Commun. 1983;112:482-7. https://doi.org/10.1016/0006-291x(83)91490-0

7. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622-9. https://doi.org/10.1016/j.cmi.2020.07.016

8. Shaw D, Abad R, Amin-Chowdhury Z, Bautista A, Bennett D, Broughton K, et al. Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: Analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium. Lancet Digit Health. 2023;5:e582-93. https://doi.org/10.1016/S2589-7500(23)00108-5

9. Secretaria de Estado da Saúde. Secretaria da Saúde registra 123% de aumento de casos de meningite em 2022. São Paulo: Secretaria de Estado da Saúde; 2023. Accessed: December 15, 2023. Available at: https://www.saude.sp.gov.br/ses/perfil/cidadao/homepage/destaques/secretaria-da-saude-registra-123-de-aumento-de-casos-de-meningite-em-2022

10. Deghmane AE, Taha MK. Changes in invasive Neisseria meningitidis and Haemophilus influenzae infections in France during the COVID-19 pandemic. Microorganisms. 2022;10:907. https://doi.org/10.3390/microorganisms10050907

11. Stein-Zamir C, Shoob H, Abramson N, Valinsky L, Jaffe J, Maimoun D, et al. Invasive disease due to Neisseria meningitidis: Surveillance and trends in Israel prior to and during the COVID-19 pandemic. Microorganisms. 2023;11:2212. https://doi.org/10.3390/microorganisms11092212

12. Steens A, Knol MJ, Freudenburg-De Graaf W, de Melker HE, van der Ende A, van Sorge NM. Pathogen-and type-specific changes in invasive bacterial disease epidemiology during the first year of the COVID-19 pandemic in The Netherlands. Microorganisms. 2022;10:972. https://doi.org/10.3390/microorganisms10050972

13. Clark SA, Campbell H, Ribeiro S, Bertran M, Walsh L, Walker A, et al. Epidemiological and strain characteristics of invasive meningococcal disease prior to, during, and after COVID-19 pandemic restrictions in England. J Infect. 2023;87:385-91. https://doi.org/10.1016/j.jinf.2023.09.002

14. Sacchi CT, Pessoa LL, Ramos SR, Milagres LG, Camargo MCC, Hidalgo NTR, et al. Ongoing group B Neisseria meningitidis epidemic in Sao Paulo, Brazil, due to increased prevalence of a single clone of the ET-5 complex. J Clin Microbiol. 1992;30:1734-8. https://doi.org/10.1128/jcm.30.7.1734-1738.1992

15. Baker MG, Martin DR, Kieft CEM, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: Descriptive epidemiology, 1991-2000. J Paediatr Child Health. 2001;37(Suppl.5):13-9. https://doi.org/10.1046/j.1440-1754.2001.00722.x

16. Klein EY, Monteforte B, Gupta A, Jiang W, May L, Hsieh YH, et al. The frequency of influenza and bacterial coinfection: A systematic review and meta-analysis. Influenza Other Respi Viruses. 2016;10:394-403. https://doi.org/10.1111/irv.12398

17. Suleiman AS, Islam MA, Akter MS, Amin MR, Wekneh AA, Bhattacharya P. A meta-analysis of co-infection, secondary infections, and antimicrobial resistance in COVID-19 patients. J Infect Public Health. 2023;16:1562-90. https://doi.org/10.1016/j.jiph.2023.07.005

18. Danino D, Ben-Shimol S, van Der Beek BA, Givon-Lavi N, Avni YS, Greenberg D, et al. Decline in pneumococcal disease in young children during the coronavirus disease 2019 (COVID-19) pandemic in Israel associated with suppression of seasonal respiratory viruses, despite persistent pneumococcal carriage: A prospective cohort study. Clin Infect Dis. 2022;75:E1154-64. https://doi.org/10.1093/cid/ciab1014

19. Gallacher SD, Seaton A. Meningococcal meningitis and COVID-19 co-infection. BMJ Case Rep. 2020;13:e237366. https://doi.org/10.1136/bcr-2020-237366

20. Ducatez N, Chancel M, Douadi Y, Dayen C, Suguenot R, Lecuyer E, et al. Primary meningococcal arthritis in a COVID-19 18-year-old man: A case report and review of the literature. BMC Infect Dis. 2021;21:499. https://doi.org/10.1186/s12879-021-06211-7

21. Valdez M, Sharma R, Joshi J, Sandhu H, Mishra S, Kuran R, et al. A double whammy pneumonia: The first reported case of concurrent Neisseria meningitidis and SARS-CoV-2 pneumonia. J Investig Med High Impact Case Rep. 2022;10:10-4. https://doi.org/10.1177/23247096221111764

22. Chacón-Cruz E, Lopatynsky EZ, Machado-Contreras JR, Gatica-Herrera R, Zazueta OE. Fatal pediatric meningococcal invasive disease caused by Neisseria meningitidis serogroup C and co-infected with SARS-CoV-2: Report of a case in Tijuana, Mexico. Cureus. 2022;14:e22100. https://doi.org/10.7759/cureus.22100

23. Salomon A, Berry I, Tuite AR, Drews S, Hatchette T, Jamieson F, et al. Influenza increases invasive meningococcal disease risk in temperate countries. Clin Microbiol Infect. 2020;26:1257.e1-1257.e7. https://doi.org/10.1016/j.cmi.2020.01.004

24. Rameix-Welti MA, Zarantonelli ML, Giorgini D, Ruckly C, Marasescu M, van Der Werf S, et al. Influenza A virus neuraminidase enhances meningococcal adhesion to epithelial cells through interaction with sialic acid-containing meningococcal capsules. Infect Immun. 2009;77:3588-95. https://doi.org/10.1128/IAI.00155-09

25. Tuite AR, Kinlin LM, Kuster SP, Jamieson F, Kwong JC, McGeer A, et al. Respiratory virus infection and risk of invasive meningococcal disease in central Ontario, Canada. PLoS ONE. 2010;5:e15493. https://doi.org/10.1371/journal.pone.0015493

26. Hoque MN, Sarkar MMH, Rahman MS, Akter S, Banu TA, Goswami B, et al. SARSCoV-2 infection reduces human nasopharyngeal commensal microbiome with inclusion of pathobionts. Sci Rep. 2021;11:24042. https://doi.org/10.1038/s41598-021-03245-4

27. Rhoades NS, Pinski AN, Monsibais AN, Jankeel A, Doratt BM, Cinco IR, et al. Acute SARSCoV-2 infection is associated with an increased abundance of bacterial pathogens, including Pseudomonas aeruginosa in the nose. Cell Rep. 2021;36:109637. https://doi.org/10.1016/j.celrep.2021.109637

28. Zhu N, Wang W, Liu Z, Liang C, Wang W, Ye F, et al. Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. Nat Commun. 2020;11:3910. https://doi.org/10.1038/s41467-020-17796-z

29. Xu JB, Guan WJ, Zhang YL, Qiu ZE, Chen L, Hou XC, et al. SARS-CoV-2 envelope protein impairs airway epithelial barrier function and exacerbates airway inflammation via increased intracellular Cl− concentration. Signal Transduct Target Ther. 2024;9:74. https://doi.org/10.1038/s41392-024-01753-z

30. Saheb Sharif-Askari N, Saheb Sharif-Askari F, Mdkhana B, Al Heialy S, Alsafar HS, Hamoudi R, et al. Enhanced expression of immune checkpoint receptors during SARSCoV-2 viral infection. Mol Ther Methods Clin Dev. 2021;20:109-21. https://doi.org/10.1016/j.omtm.2020.11.002

31. Nunnari G, Sanfilippo C, Castrogiovanni P, Imbesi R, Li Volti G, Barbagallo I, et al. Network perturbation analysis in human bronchial epithelial cells following SARS-CoV2 infection. Exp Cell Res. 2020;395:112204. https://doi.org/10.1016/j.yexcr.2020.112204

32. Petruk G, Puthia M, Petrlova J, Samsudin F, Strömdahl AC, Cerps S, et al. SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity. J Mol Cell Biol. 2020;12:916-32. https://doi.org/10.1093/jmcb/mjaa067

33. Basu S, Ashok G, Debroy R, Ramaiah S, Anbarasu A, Livingstone P. Impact of the COVID-19 pandemic on routine vaccine landscape: A global perspective. Hum Vaccin Immunother. 2023;19:2199656. https://doi.org/10.1080/21645515.2023.2199656

34. Moura C, Truche P, Sousa Salgado L, Meireles T, Santana V, Buda A, et al. The impact of COVID-19 on routine pediatric vaccination delivery in Brazil. Vaccine. 2022;40:2292-8. https://doi.org/10.1016/j.vaccine.2022.02.076

35. Yunusa A, Cabral C, Anderson E. The impact of the COVID-19 pandemic on the uptake of routine maternal and infant vaccines globally: A systematic review. PLoS Glob Public Health. 2022;2:e0000628. https://doi.org/10.1371/journal.pgph.0000628

36. Sulis G, Horn M, Borrow R, Basta NE. A comparison of national vaccination policies to prevent serogroup B meningococcal disease. Vaccine. 2022;40:3647-54. https://doi.org/10.1016/j.vaccine.2022.04.101

37. Ministério da Saúde do Brasil. Guia de Vigilância em Saúde. 5a edição. Guia de Vigilância em Saúde. Brasília: Ministério da Saúde do Brasil; 2022. p. 1126. Accessed: March 11, 2025. Available at: https://bvsms.saude.gov.br/bvs/publicacoes/guia_vigilancia_saude_5ed_rev_atual.pdf

38. Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382:309-17. https://doi.org/10.1056/NEJMoa1901229

39. Lodi L, Barbati F, Amicizia D, Baldo V, Barbui AM, Bondi A, et al. Four-component recombinant protein-based vaccine effectiveness against serogroup B meningococcal disease in Italy. JAMA Netw Open. 2023;6:E2329678. https://doi.org/10.1001/jamanetworkopen.2023.29678

40. Wang B, Giles L, Andraweera P, McMillan M, Almond S, Beazley R, et al. 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post-programme implementation. J Infect. 2023;87:95-102. https://doi.org/10.1016/j.jinf.2023.05.021

41. Biolchi A, De Angelis G, Moschioni M, Tomei S, Brunelli B, Giuliani M, et al. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W, and Y invasive disease isolates. Vaccine. 2020;38:7542-50. https://doi.org/10.1016/j.vaccine.2020.09.050

42. Drazan D, Czajka H, Maguire JD, Pregaldien JL, Maansson R, O’Neill R, et al. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults. Vaccine. 2022;40:351-8. https://doi.org/10.1016/j.vaccine.2021.11.053

43. Lujan E, Partridge E, Giuntini S, Ram S, Granoff DM. Breadth and duration of meningococcal serum bactericidal activity in health care workers and microbiologists immunized with the MenB-FHbp vaccine. Clin Vaccine Immunol. 2017;24:e00121-17. https://doi.org/10.1128/CVI.00121-17

44. Soeters HM, Whaley M, Alexander-Scott N, Kanadanian KV, MacNeil JR, Martin SW, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a College –Rhode Island, 2015-2016. Clin Infect Dis. 2017;64:1115-22. https://doi.org/10.1093/cid/cix091

45. Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384:2123-31. https://doi.org/10.1016/S0140-6736(14)60842-4

46. McMillan M, Walters L, Sullivan T, Leong LEX, Turra M, Lawrence A, et al. Impact of meningococcal B (4CMenB) vaccine on pharyngeal Neisseria meningitidis carriage density and persistence in adolescents. Clin Infect Dis. 2021;73:E99-106. https://doi.org/10.1093/cid/ciaa610

47. Moura Silveira M, McBride AJA, Trotter CL. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme. Vaccine. 2019;37:6783-6. https://doi.org/10.1016/j.vaccine.2019.09.062

48. Izquierdo G, Torres JP, Santolaya ME, Valenzuela MT, Vega J, Chomali M. Costeffectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country. Hum Vaccin Immunother. 2015;11:875-83. https://doi.org/10.1080/21645515.2015.1010885

49. Schley K, Jodar E, Presa JV, Willis SJ, Prener CG. The impact of regional disparities on the availability of meningococcal vaccines in the US. BMC Public Health. 2024;24:1771. https://doi.org/10.1186/s12889-024-19081-w

50. George CR, Booy R, Nissen MD, Lahra MM. The decline of invasive meningococcal disease and influenza in the time of COVID-19: The silver linings of the pandemic playbook. Med J Aust. 2022;216:504-7. https://doi.org/10.5694/mja2.51463

51. Bloom DE, Bonanni P, Martinón-Torres F, Richmond PC, Safadi MAP, Salisbury DM, et al. Meningococcal disease in the post-COVID-19 era: A time to prepare. Infect Dis Ther. 2023;12:2649-63. https://doi.org/10.1007/s40121-023-00888-w

Cómo citar
1.
Izeli Portilho A, De Gaspari E. ¿Es necesaria la vacunación contra el meningococo B en el mundo pos-COVID-19?. Biomed. [Internet]. 11 de agosto de 2025 [citado 2 de marzo de 2026];45(3):359-68. Disponible en: https://revistabiomedicaorg.biteca.online/index.php/biomedica/article/view/7423
Publicado
2025-08-11
Número
Vol. 45 Núm. 3 (2025)
Sección
Ensayo

Derechos de autor 2025 Biomédica

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.

Métricas

Estadísticas de artículo
Vistas de resúmenes
Vistas de PDF
Descargas de PDF
Vistas de HTML
Otras vistas

Datos de los fondos

Crossref Cited-by logo
Escanea para compartir
QR Code